Grant ID RP230345
Awarded On February 15, 2023
Title The Development of Reversible Chemogenetic Switches for Chimeric Antigen Receptor T Cell Therapy
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization Texas A&M University
Principal Investigator/Program Director Wenshe Liu
Cancer Sites Leukemia, Lymphoma, Myeloma
Contracted Amount $1,050,000
Lay Summary

The development of chimeric antigen receptor (CAR) T cell therapeutics has revolutionized clinical intervention of cancer. Crowned as live drugs, CAR-T cell therapy has demonstrated success in the elimination of hematopoietic tumors including different types of leukemia, lymphoma and myeloma. Several CAR-T therapeutics have been clinically approved. Many others are on clinical trials. Although extremely powerful, CAR-T cell therapy suffers from serious safety concerns including cytokine release syndrome, neurological toxicity, tumor lysis syndrome, on-target/off-tumor toxicity, anaphylaxis, and hematological toxicity. Besides safety concerns, there are other challenges that limit efficacy of...

Read More